Scinai Immunotherapeutics annual return on equity
2020
2021
2022
2024
2025
Scinai Immunotherapeutics Return on Equity (ROE) Growth & History (SCNI)
Scinai Immunotherapeutics's return on equity was −91.89% for fiscal 2025.
View full Scinai Immunotherapeutics company overviewScinai Immunotherapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −91.89% | −269.26 pp |
| 2024 | 2024-12-31 | 177.37% | — |
| 2022 | 2022-12-31 | −53.73% | +83.06 pp |
| 2021 | 2021-12-31 | −136.80% | −113.07 pp |
| 2020 | 2020-12-31 | −23.72% | — |
Scinai Immunotherapeutics quarterly return on equity
Q2.22
Q4.24
Q2.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −17.05% | +11.85 pp |
| Q1 2026 | 2026-03-31 | 36.01% | — |
| Q2 2025 | 2025-06-30 | −28.90% | — |
| Q4 2024 | 2024-12-31 | −165.61% | — |
| Q2 2022 | 2022-06-30 | −24.24% | — |
Scinai Immunotherapeutics return on equity trends
Over the last five fiscal years, Scinai Immunotherapeutics's return on equity decreased from −23.72% to −91.89%, a change of −68.17 percentage points. The latest reported quarter, Q2 2026, shows −17.05%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Scinai Immunotherapeutics source filings ↗